SZN 8141
Alternative Names: SZN-8141Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Surrozen
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action FZD4 protein stimulants; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Diabetic macular oedema
Most Recent Events
- 06 Nov 2024 Preclinical trials in Age-related macular degeneration in USA (Parenteral) prior to November 2024 (Surrozen pipeline, November 2024)
- 06 Nov 2024 Preclinical trials in Diabetic macular oedema in USA (Parenteral) prior to November 2024 (Surrozen pipeline, November 2024)
- 06 Nov 2024 Pharmacodynamics data from preclinical studies in Retinal disorders released by Surrozen